Mechanisms of CAF-Induced Chemoresistance in Prostate Cancer: The ANGPTL4-IQGAP1 Axis

Study Background and Research Question

Prostate cancer (PCa) remains a leading malignancy in men, with advanced stages frequently developing resistance to chemotherapy and androgen deprivation therapy. The tumor microenvironment (TME), and specifically cancer-associated fibroblasts (CAFs), has been increasingly recognized as a driver of this therapeutic resistance. However, the molecular mediators responsible for the influence of CAFs on PCa cell metabolism and chemosensitivity are incompletely understood. The reference study (Journal of Advanced Research, 2025) aimed to elucidate how CAFs modulate mitochondrial metabolism and contribute to the development of chemoresistance in PCa, focusing on the ANGPTL4-IQGAP1 signaling axis.

Key Innovation from the Reference Study

The primary innovation of the study lies in the identification of a paracrine mechanism wherein CAF-derived angiopoietin-like protein 4 (ANGPTL4) binds to the IQGAP1 receptor on the surface of prostate cancer cells. This interaction activates the Raf-MEK-ERK-PGC1α pathway, leading to enhanced mitochondrial biogenesis and oxidative phosphorylation (OXPHOS) in tumor cells. By establishing this direct link between stromal signaling and mitochondrial reprogramming, the study provides a mechanistic explanation for decreased chemosensitivity in PCa and highlights new molecular targets for intervention.

Methods and Experimental Design Insights

The research combined proteomic, metabolomic, and functional assays to dissect the interactions between CAFs and PCa cells. Key methodological steps included:

• CAF Isolation and Characterization: Primary CAFs were isolated from human PCa tissues and their conditioned media (CM) were collected for downstream analysis.
• Proteomic Analysis: Comprehensive profiling of CAF and PCa cell CM identified ANGPTL4 as a CAF-enriched secreted factor.
• ELISA and Multiplex Immunofluorescence: Validated the predominant secretion of ANGPTL4 by CAFs within the TME.
• Metabolomics: Assessed metabolic changes in PCa cells following exposure to CAF CM, revealing increased mitochondrial biogenesis and OXPHOS activity.
• Protein Interaction Assays: GST pull-down and co-immunoprecipitation (co-IP) experiments confirmed the binding of ANGPTL4 to IQGAP1 on PCa cell membranes.
• Drug Screening: Identified Quercetin 3-O-(6′-galactopyranosyl)-β-D-galactopyranoside (QGGP) as a functional inhibitor of the CAF-ANGPTL4 axis, with potential to enhance chemosensitivity.
• In Vitro and In Vivo Functional Assays: Evaluated the impact of disrupting the ANGPTL4-IQGAP1 pathway on PCa cell proliferation, mitochondrial metabolism, and response to chemotherapy.

Throughout these workflows, careful sample handling and the use of appropriate lysis buffers with protease and phosphatase inhibitor cocktails were critical for preserving native protein-protein interactions, as recommended for co-IP and immunoprecipitation sample preparation (related protocol insights).

Core Findings and Why They Matter

The study's main findings can be summarized as follows:

• CAFs promote chemotherapy resistance in prostate cancer by enhancing mitochondrial biogenesis and OXPHOS metabolism within PCa cells.
• ANGPTL4 is primarily secreted by CAFs and acts in a paracrine manner to activate IQGAP1 on the PCa cell surface.
• Activation of the Raf-MEK-ERK-PGC1α signaling cascade leads to metabolic reprogramming, fostering a chemoresistant phenotype.
• Targeting the ANGPTL4-IQGAP1 axis with small molecule inhibitors such as QGGP can sensitize PCa cells to standard therapies, including docetaxel.

These findings deepen our understanding of how stromal-tumor metabolic crosstalk contributes to drug resistance and suggest that interrupting this axis could improve clinical outcomes for patients with advanced PCa. The implications extend to the design of combination therapies that jointly target tumor cells and their supportive microenvironment.

Comparison with Existing Internal Articles

Several recent internal articles provide complementary protocol strategies and mechanistic context for this study. For example, "CAFs Drive Chemoresistance in Prostate Cancer via ANGPTL4-IQGAP1 Axis" summarizes the mechanistic insights and highlights the translational relevance of targeting metabolic drivers of drug resistance. Meanwhile, "Next-Gen Cell Lysis: Empowering Tumor Microenvironment Assays" discusses the importance of robust protein extraction for Western blot and co-IP workflows when interrogating signaling pathways in complex TME settings. These resources reinforce the necessity of using optimized lysis buffers with broad-spectrum inhibitor cocktails for high-fidelity protein extraction and protein degradation prevention, especially in studies involving dynamic protein complexes.

Protocol Parameters

• CAF-conditioned media preparation: Culture primary CAFs until 80% confluence, then switch to serum-free medium for 24–48 hours before collecting CM.
• Protein extraction for Western blot or co-IP: Use a non-denaturing cell lysis buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton X-100, and a comprehensive protease and phosphatase inhibitor cocktail to prevent protein degradation and preserve interaction complexes.
• Immunoprecipitation sample preparation: Pre-clear lysates with control IgG and protein A/G beads, then incubate with primary antibody overnight at 4°C before adding beads for 2–4 hours.
• Metabolomics sample handling: Rapidly quench cells and extract metabolites in cold solvents to prevent post-harvest metabolic changes.
• Drug treatment assays: Treat PCa cells with QGGP or docetaxel alone and in combination to assess chemosensitivity changes.

Limitations and Transferability

While the study provides compelling mechanistic evidence for CAF-driven metabolic reprogramming in PCa, several limitations should be acknowledged. The primary models were based on human cell lines and xenografts, which may not fully capture the complexity of patient tumors or diverse CAF subtypes. The identified ANGPTL4-IQGAP1 pathway may also interact with additional stromal or immune components that were not directly evaluated. Transferability of these findings to other solid tumors or to clinical settings will require further validation, including assessment of off-target effects and the specificity of QGGP or related inhibitors.

Research Support Resources

For researchers aiming to replicate or extend these findings, high-quality reagents for protein extraction and immunoprecipitation are essential. The Cell lysis buffer for WB and IP (SKU K1123) from APExBIO offers a non-denaturing formulation with an advanced protease and phosphatase inhibitor cocktail, supporting reliable protein extraction from animal and plant tissue lysis and preserving native protein-protein interactions for downstream Western blot, co-IP, and ELISA applications. Proper buffer selection is especially critical when studying dynamic processes such as those involving the ANGPTL4-IQGAP1 axis in the tumor microenvironment.